Evidence map›Paper›PMID 20697352›Full record

ReviewOncogene2010

Binding of pro-prion to filamin A: by design or an unfortunate blunder.

C Li, W Xin, M-S Sy

Open access · greenAbstract readReview
In one paragraph

Review in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The Cellular Prion Protein: A Promising Therapeutic Target for Cancer.International journal of molecular sciences · 2020
    Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

C LiDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-7288, USA.
W Xin
M-S Sy
Case Western Reserve University · USUniversity Hospitals Case Medical Center · US

Funding

Vitamin D endocrine system and Protection Against Skin TumorlgenesisP30AR039750 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, KEVIN D · 1988 to 2015
$9.1M
Normal Cellular Prion Protein in Pancreatic CancerR21CA133559 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI SY, MAN-SUN M · 2008 to 2009
$387k
NCI NIH HHS R21 CA133559NCI NIH HHS R21-CA133559-01NIAMS NIH HHS 5P30AR039750NIAMS NIH HHS P30 AR039750
6 · The paper itself

Abstract

Over the last decades, cancer research has focused on tumor suppressor genes and oncogenes. Genes in other cellular pathways has received less attention. Between 0.5% to 1% of the mammalian genome encodes for proteins that are tethered on the cell membrane via a glycosylphosphatidylinositol (GPI)-anchor. The GPI modification pathway is complex and not completely understood. Prion (PrP), a GPI-anchored protein, is infamous for being the only normal protein that when misfolded can cause and transmit a deadly disease. Though widely expressed and highly conserved, little is known about the functions of PrP. Pancreatic cancer and melanoma cell lines express PrP. However, in these cell lines the PrP exists as a pro-PrP as defined by retaining its GPI anchor peptide signal sequence (GPI-PSS). Unexpectedly, the GPI-PSS of PrP has a filamin A (FLNA) binding motif and binds FLNA. FLNA is a cytolinker protein, and an integrator of cell mechanics and signaling. Binding of pro-PrP to FLNA disrupts the normal FLNA functions. Although normal pancreatic ductal cells lack PrP, about 40% of patients with pancreatic ductal cell adenocarcinoma express PrP in their cancers. These patients have significantly shorter survival time compared with patients whose cancers lack PrP. Pro-PrP is also detected in melanoma in situ but is undetectable in normal melanocyte, and invasive melanoma expresses more pro-PrP. In this review, we will discuss the underlying mechanisms by which binding of pro-PrP to FLNA disrupts normal cellular physiology and contributes to tumorigenesis, and the potential mechanisms that cause the accumulation of pro-PrP in cancer cells.

Indexed as

Carcinoma, Pancreatic DuctalCell Line, TumorCell MembraneContractile ProteinsFilaminsGlycosylphosphatidylinositolsHumansMelanomaMicrofilament ProteinsPancreatic NeoplasmsPrionsProtein BindingProtein PrecursorsSignal TransductionContractile ProteinsFilaminsGlycosylphosphatidylinositolsMicrofilament ProteinsPrionsProtein Precursors

Identifiers

PMID20697352
PMCPMC3159184
OpenAlexW2086965783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.